DoP exempts pharmaceutical companies from lowering drug prices based on WPI

NPPA insisted that all companies revise prices based on WPI even if prices are below ceiling price

In a relief to the pharmaceutical industry, the Department of Pharmaceuticals has ordered that companies already selling drugs at a price lesser than the ceiling price fixed by the NPPA will not have to revise prices based on the Wholesale Price Index. 

The Department of Pharmaceuticals said that the pharma pricing regulator "erred" when it said that even prices of the drugs with Maximum Retail Price below the actual ceiling price fixed by the NPPA should be revised. The Department's order says, "NPPA is therefore directed to revise the Ceiling Price of Schedule I medicines each year in accordance with